menu
    • menu
    [{"orgOrder":0,"company":"GeneFab","sponsor":"Senti Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"SENTI-202","moa":"CD33\/FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"GeneFab","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Inhalation","sponsorNew":"GeneFab \/ GeneFab","highestDevelopmentStatusID":"6","companyTruncated":"GeneFab \/ GeneFab"},{"orgOrder":0,"company":"GeneFab","sponsor":"RegCell","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"GeneFab","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneFab \/ RegCell","highestDevelopmentStatusID":"4","companyTruncated":"GeneFab \/ RegCell"}]

    Find Clinical Drug Pipeline Developments & Deals by GeneFab

    Menu

    GeneFab

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GeneFab

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GeneFab

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : RegCell

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            GeneFab & RegCell Partner for Treg Therapy Manufacturing in the U.S.

                            Details : The partnership will support the tech transfer and clinical manufacturing of RegCell’s Treg platform and accelerate U.S. clinical trials for autoimmune indications, including autoimmune hepatitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 07, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : RegCell

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GeneFab

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            GeneFab

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Senti Biosciences

                            Deal Size : $38.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufa...

                            Details : Under the partnership, GeneFab will support manufacturing of Senti’s chimeric antigen receptor natural killer (CAR-NK) medicines pipeline, including SENTI-202, for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as AML and M...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $38.0 million

                            August 10, 2023

                            Lead Product(s) : SENTI-202

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Senti Biosciences

                            Deal Size : $38.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth